VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Results of the Phase III PERSIST-1 trial of pacritinib for myelofibrosis

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the phase 3 PERSIST-1 trial, which compared the efficacy and safety of pacritinib, a Janus kinase 2 inhibitor, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter